Financial Performance - The company reported a significant increase in revenue, achieving a total of 342 million in 2022, reflecting a growth of 15% year-over-year[11]. - The company reported a total revenue of 1.2 billion RMB for the fiscal year 2022, representing a year-over-year growth of 15%[16]. - The company's operating revenue for 2022 was CNY 4,230,800,610, representing a year-on-year increase of 7.69%[22]. - The total profit reached 2,531.39 million RMB, showing a significant increase of 324.70% compared to the previous year[44]. - The net profit attributable to shareholders for 2022 reached CNY 2,026,449,580, a significant increase of 319.04% compared to the previous year, primarily due to a settlement with Illumina resulting in a net compensation of USD 325 million[25]. - The net profit attributable to shareholders after deducting non-recurring gains and losses decreased by 46.43% to CNY 264,109,949.78, influenced by changes in market demand and an increase in R&D expenses[25]. - The company achieved a main business revenue of CNY 4,206.88 million, an increase of 7.96% year-on-year, while the main business cost rose by 50.19% to CNY 1,952.75 million[158]. - The gross profit margin for the specialized equipment manufacturing industry decreased by 13.05 percentage points to 53.58%[158]. Dividend and Share Capital - The company plans to distribute a cash dividend of RMB 3.60 per 10 shares, totaling RMB 149,160,502.80, which represents 7.36% of the net profit attributable to shareholders for 2022[4]. - As of December 31, 2022, the total share capital of the company was 414,334,730 shares[4]. Research and Development - Investment in R&D is set to increase by 15% in 2023, emphasizing innovation and the development of cutting-edge technologies[12]. - The company reported a total R&D investment of approximately ¥814.37 million, representing a 33.88% increase compared to the previous year, and accounting for 19.25% of total revenue[122]. - The number of R&D personnel increased by 42.25% to 1,010, with R&D staff now comprising 36.01% of the total workforce[121]. - The R&D expenditure as a percentage of operating revenue was 19.25%, an increase of 3.77 percentage points compared to the previous year[24]. Market Expansion and Strategy - The company provided a positive outlook for 2023, projecting a revenue growth of 20% driven by new product launches and market expansion initiatives[12]. - The company is planning to expand its market presence in Southeast Asia, targeting a 30% increase in market share within the next two years[12]. - Strategic acquisitions are on the agenda, with plans to acquire two smaller biotech firms to bolster R&D capabilities and product offerings[12]. - The company is focusing on increasing its international sales, with a goal of achieving 40% of total revenue from overseas markets by 2025[12]. - The company has established five new subsidiaries in key global markets, including the USA and Brazil, and opened five customer experience centers to enhance local business development and support[36]. Operational Efficiency - The company aims to enhance its operational efficiency, targeting a reduction in costs by 10% through process optimization and technology integration[12]. - Future guidance indicates an expected EBITDA margin improvement to 25% by the end of 2023, up from 20% in 2022[12]. Governance and Compliance - The board of directors has confirmed the authenticity, accuracy, and completeness of the annual report[4]. - The company has not disclosed any special arrangements for corporate governance[6]. - The governance structure includes a clear division of responsibilities among the shareholders' meeting, board of directors, supervisory board, and senior management, ensuring effective and stable operations[200]. - The company has established various governance rules and management systems to ensure compliance with laws and regulations, providing a framework for standardized corporate governance[200]. Risks and Challenges - The company has detailed various operational risks in the report, which can be found in the "Management Discussion and Analysis" section[3]. - The company faces risks related to product upgrades and technological updates, which could impact future performance if not managed effectively[133]. - The company is subject to various intellectual property litigation risks across 20 countries, which may impact its business operations and market expansion[135]. - The company is facing risks related to the loss of core technical talent and potential leakage of core technologies due to intensified competition in the industry[134]. Product Development and Innovation - New product development includes the introduction of the stLFR technology, which is expected to enhance genomic analysis capabilities and attract new customers[12]. - The company launched the DNBSEQ-T20×2 ultra-high-throughput sequencer, capable of reducing the cost of whole genome sequencing to below $100[33]. - The company has commercialized 12 types of sequencing proteins, delivering over 660 liters, and is set to begin production of 19 types of dNTP products at its Wuhan base in 2023[39]. - The company has developed a full range of gene sequencers, including small desktop sequencers and large-scale sequencers, to meet diverse user needs in various application scenarios[127]. Customer and Supplier Relationships - The company’s top five customers contributed CNY 1,354.50 million in sales, accounting for 32.02% of total annual sales, with related party sales making up 18.33%[166]. - The top five suppliers accounted for 33.16% of total procurement, with the largest supplier contributing 507,471,841.37 RMB, or 15.93% of total procurement[169]. - The company did not rely heavily on a single supplier or customer, as indicated by the absence of significant dependency on the top five suppliers and customers[168][169]. International Operations - The company has expanded its global business network, employing over 2,800 people and establishing 21 overseas subsidiaries across various countries[46]. - The company aims to enhance its global market presence by establishing training, logistics, and R&D centers across four major regions: China, Asia-Pacific, Europe, and the Americas[191]. Financial Management - The company plans to mitigate foreign exchange risks by utilizing forward foreign exchange contracts and adjusting currency holdings based on funding needs[146]. - The company’s cash flow from operating activities increased by 32.43% to CNY 1,421,245,347.84, driven by the compensation received from Illumina[156].

Financial Performance - The company reported a total revenue of $1.8 billion for the fiscal year 2022, representing a 15% increase year-over-year [13]. - The company's operating revenue for 2022 was CNY 4,230,800,610, representing a year-on-year increase of 7.69% [24]. - The total profit reached 2,531.39 million yuan, reflecting a significant year-on-year growth of 324.70% [65]. - The net profit attributable to shareholders increased by 319.04% to CNY 2,026,449,580, primarily due to a settlement with Illumina resulting in a net compensation of USD 325 million [27]. - The net profit attributable to shareholders after deducting non-recurring gains and losses decreased by 46.43% to CNY 264,109,949, influenced by changes in product sales structure and increased R&D expenses [27]. - The net cash flow from operating activities rose by 32.43% to CNY 1,421,245,347, also benefiting from the Illumina settlement [27]. - Basic earnings per share grew by 304.62% to CNY 5.26, reflecting the significant increase in net profit [26]. - Diluted earnings per share also rose by 304.65% to CNY 5.22, consistent with the net profit growth [26]. Dividend and Share Capital - The company plans to distribute a cash dividend of RMB 3.60 per 10 shares, totaling RMB 149,160,502.80, which represents 7.36% of the net profit attributable to shareholders for 2022 [5]. - The total share capital as of December 31, 2022, is 414,334,730 shares [5]. Research and Development - Investment in R&D increased by 30%, focusing on new technologies and product development [14]. - The R&D expenditure as a percentage of operating revenue increased to 19.25%, up from 15.48% in the previous year [26]. - In 2022, the company invested CNY 814.37 million in R&D, a year-on-year increase of 33.88%, accounting for 19.25% of total revenue [42]. - The company applied for 369 new patents and obtained 123 patents, including 85 invention patents, enhancing its core technology capabilities [42]. - The company has developed core technologies in various fields, including high-precision temperature control and automated sample processing, all sourced from independent research and development [153]. Market Expansion and Strategy - The company expects revenue growth of 20% for the next fiscal year, driven by new product launches and market expansion [14]. - The company plans to expand its market presence in Asia, targeting a 15% market share by 2025 [14]. - The company is focusing on expanding its market presence in Europe and the Americas with tailored product versions [12]. - The company has established a global business network, with access to major markets across six continents and R&D centers in the USA and Latvia, enhancing its international presence [178]. Product Development and Innovation - The company launched a new product line that is expected to contribute $200 million in revenue in the first year [14]. - The company launched multiple new product series, including the E, G, and T series in gene sequencing instruments, and various automation devices in laboratory automation [40]. - The company has developed high-throughput single-cell sequencing kits, achieving a cell capture rate of 50%-70% [14]. - The company introduced the DNBSEQ-G99 product, a small to medium throughput instrument, which can complete PE150 sequencing in 12 hours, suitable for small sample applications [145]. - The company launched the HotMPS high-throughput sequencing kit in several European countries, compatible with DNBSEQ-T7 and DNBSEQ-G400 series, featuring new sequencing substrates and enzymes [79]. Operational Risks and Governance - The company has detailed various operational risks in the report, which can be found in the section on risk factors [4]. - The company has not disclosed any special arrangements for corporate governance [7]. - The company has no non-operating fund occupation by controlling shareholders or related parties [7]. - There are no violations of decision-making procedures regarding external guarantees [7]. Market Conditions and Competition - The company operates in a highly competitive gene sequencing market, with Illumina and Thermo Fisher holding over 90% market share, posing significant competition risks [186]. - The company is at risk of fluctuating gross margins due to varying prices and profit margins across its diverse product matrix [193]. - The company acknowledges the potential negative impacts of international trade tensions on its overseas business operations, which could affect sales and growth [200]. Employee and Talent Management - The company employs over 2,800 staff globally, with 1,010 in R&D, representing 36.01% of the workforce, emphasizing its focus on talent acquisition [63]. - The R&D team consists of 1,010 personnel, accounting for approximately 36.01% of total employees, with over 50% holding master's degrees or higher, driving continuous innovation in gene sequencing and laboratory automation [180]. - The company has established a comprehensive training system to enhance employee skills and core competitiveness [64]. Settlements and Legal Matters - The company reached a settlement with Illumina, resulting in a net compensation of $325 million, allowing it to officially enter the U.S. market for sequencing products [50]. - The company is subject to potential impacts from ongoing intellectual property litigation in multiple countries, which could affect its market expansion [184]. Quality Management and Certifications - The company has established a comprehensive quality management system, obtaining 33 global certifications, including 8 international standards and 4 drug regulatory approvals [54]. - The company achieved a cumulative total of 213 medical device registrations and certifications, including 24 domestic and 189 foreign [155].

Financial Performance - The company's revenue for Q1 2023 was ¥619,002,726.63, representing a decrease of 49.25% compared to the same period last year[4] - The net profit attributable to shareholders was -¥149,816,707.55, a decline of 143.78% year-over-year[4] - The net cash flow from operating activities was -¥451,671,394.87, reflecting a decrease of 493.91% compared to the previous year[4] - The basic earnings per share were -¥0.36, a decrease of 139.13% compared to the same period last year[4] - Total operating revenue for Q1 2023 was ¥619,002,726.63, a decrease of 49.2% compared to ¥1,219,792,640.81 in Q1 2022[27] - Net loss for Q1 2023 was ¥150,045,829.72, compared to a net profit of ¥342,050,181.17 in Q1 2022[28] - Other comprehensive income after tax for Q1 2023 was -¥20,173,635.34, compared to -¥10,493,513.28 in Q1 2022[28] - The company reported a comprehensive loss of ¥170,219,465.06 in Q1 2023, compared to a comprehensive income of ¥331,556,667.89 in Q1 2022[28] Research and Development - Research and development expenses totaled ¥218,799,003.24, an increase of 40.10% year-over-year, accounting for 35.35% of total revenue, up 22.54 percentage points[6] - R&D expenses increased to ¥218,799,003.24 in Q1 2023, up 40.0% from ¥156,167,891.07 in Q1 2022[27] - The company plans to continue investing in technology and product innovation in areas such as gene sequencing instruments and automation systems[10] Assets and Liabilities - The total assets at the end of the reporting period were ¥10,721,111,718.51, a decrease of 4.43% from the end of the previous year[6] - As of March 31, 2023, the company's total assets amounted to approximately ¥10.72 billion, a decrease from ¥11.22 billion as of December 31, 2022[24] - Total liabilities decreased to ¥1,435,574,221.97 in Q1 2023 from ¥1,765,726,951.92 in Q1 2022, a reduction of 18.6%[26] - Total equity decreased to ¥9,285,537,496.54 in Q1 2023 from ¥9,452,593,954.56 in Q1 2022, a decline of 1.8%[26] Cash Flow - The company's cash and cash equivalents decreased to approximately ¥5.92 billion from ¥6.48 billion year-over-year[24] - The net cash outflow from operating activities was ¥451,671,394.87, contrasting with a net inflow of ¥114,664,822.75 in the same period last year[30] - Cash outflows for purchasing goods and services amounted to ¥569,709,074.92, down from ¥639,661,123.15 in Q1 2022, indicating a reduction of about 11%[30] - The company experienced a net cash outflow from investing activities of ¥58,564,670.42, compared to a smaller outflow of ¥13,794,184.28 in Q1 2022[31] - Cash outflows related to financing activities totaled ¥19,558,891.20, which is an increase from ¥11,131,869.97 in the previous year[31] - The net decrease in cash and cash equivalents for the quarter was ¥557,075,740.90, contrasting with an increase of ¥76,774,763.74 in Q1 2022[31] - The ending balance of cash and cash equivalents was ¥5,911,909,785.68, down from ¥2,662,223,101.48 at the end of Q1 2022[31] Market and Product Developments - The decline in revenue was primarily due to a decrease in demand for automation products[9] - The company launched its full range of sequencing products in the U.S. in January 2023, enhancing sequencing capabilities for users across various fields[21] - The newly released DNBSEQ-T20×2 sequencing instrument achieves a single-run throughput of 42Tb (PE100) or 72Tb (PE150), significantly reducing the cost of whole genome sequencing to below $100[22] - The European Patent Office declared Illumina's patent invalid, allowing the company to sell its full range of sequencing instruments in multiple European countries[23] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 8,724[11] Employee Compensation - The company reported a significant reduction in employee compensation liabilities, decreasing from approximately ¥277.29 million to ¥145.79 million[25] - Employee compensation payments rose to ¥441,555,569.23, up from ¥289,413,445.54 in Q1 2022, reflecting a significant increase of about 53%[30]

证券代码：688114 证券简称：华大智造 公告编号：2023- 012 关于参加 2022 年度医疗器械集体业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议线上交流时间：2023 年 4 月 28 日(星期五)上午 9:00-11:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （网址： http://roadshow.sseinfo.com/） 会议召开方式：视频和线上文字互动 投资者可于 2023 年 4 月 27 日(星期四)16:00 前通过邮件、电话、传真等形 式将需要了解和关注的问题提前提供给公司。公司将在文字互动环节对投资者普 遍关注的问题进行回答。 深圳华大智造科技股份有限公司（以下简称"公司"）将于 2023 年 4 月 25 日发布《2022 年年度报告》，为便于广大投资者更全面深入地了解公司 2022 年 度经营成果、财务状况、发展理念，公司参与了由上海证券交易所主办的 2022 年 度医疗器械集体业绩说明会，此次活动将采用视频 ...

Financial Performance - The company's operating revenue for Q3 2022 was ¥928,958,162.52, representing a year-over-year increase of 4.63%[4]. - The net profit attributable to shareholders for Q3 2022 was ¥1,678,255,089.16, with a year-to-date increase of 339.85% to ¥4,717,830,352.49[4][9]. - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2022 was ¥44,033,703.73, showing a year-to-date decrease of 24.96%[4]. - The basic earnings per share for Q3 2022 was ¥4.39, with a year-to-date increase of 334.32% to ¥4,582.08[5][9]. - The total profit for the period is approximately CNY 2.62 billion, compared to CNY 541.38 million in the previous period, indicating a significant increase[33]. - The net profit attributable to shareholders of the parent company is approximately CNY 2.02 billion, up from CNY 459.69 million year-over-year[35]. - The basic earnings per share (EPS) is CNY 5.39, compared to CNY 1.24 in the previous period, reflecting a substantial growth in profitability[35]. - The company reported a total comprehensive income for the period of approximately CNY 2.12 billion, compared to CNY 444.12 million in the previous period, indicating robust overall performance[35]. Assets and Liabilities - The total assets at the end of Q3 2022 reached ¥11,736,266,013.61, reflecting a 97.47% increase compared to the same period last year[5][10]. - The equity attributable to shareholders at the end of Q3 2022 was ¥9,411,389,087.31, an increase of 134.87% year-over-year[5][10]. - The total liabilities increased to CNY 2.28 billion from CNY 1.87 billion, representing a growth of 21.9%[30]. - Current assets rose to CNY 9.83 billion, compared to CNY 4.27 billion in the previous year, marking an increase of 130.5%[23]. Cash Flow - The net cash flow from operating activities for the year-to-date period was ¥2,072,381,921.40, reflecting a 250.19% increase[5][9]. - Cash inflows from operating activities totaled approximately CNY 5.66 billion, compared to CNY 3.51 billion in the previous year, showing a strong operational performance[36]. - The net cash flow from operating activities is approximately CNY 2.07 billion, a significant increase from CNY 591.79 million in the previous period[37]. - The company reported a net increase in cash and cash equivalents of approximately CNY 5.23 billion, compared to a decrease of CNY 529.98 million in the previous year[39]. - The company has successfully managed its financial activities, with cash inflows from financing activities amounting to approximately CNY 3.35 billion, compared to CNY 30 million in the previous year[37]. Research and Development - Research and development expenses for Q3 2022 totaled ¥193,767,510.81, accounting for 20.86% of operating revenue, which is an increase of 1.37 percentage points[5]. - Research and development expenses for the third quarter of 2022 were CNY 525.32 million, up from CNY 456.54 million in the same quarter of 2021, indicating a growth of 15.0%[32]. - The company plans to continue expanding its market presence and investing in R&D to enhance product offerings and technological advancements[5]. - The company has ongoing investments in new technologies and products, with a focus on expanding its market presence and enhancing R&D capabilities[31]. Shareholder Information - The total number of common shareholders at the end of the reporting period was 7,587[11]. - Shenzhen BGI Intelligent Manufacturing Co., Ltd. holds 153,001,440 shares, accounting for 37.04% of the total shares[11]. - The top ten shareholders include CPE Investment (Hong Kong) 2018 Limited, holding 26,378,788 shares, which is 6.39% of the total shares[11]. - The company has not disclosed any related party transactions or concerted actions among the top ten shareholders beyond those mentioned[14]. Impairment Losses - The company recognized credit impairment losses of RMB 22,445,113.23 for accounts receivable and RMB 536,470.58 for other receivables during the reporting period[17]. - The total asset impairment losses for the first nine months of 2022 amounted to RMB 59,057,585.15, which will reduce the total profit for the consolidated financial statements[17]. - The company reported a credit impairment loss of RMB 36,076,001.34 for inventory during the reporting period[17]. Strategic Plans - The company plans to jointly bid for land in Yantian District with Shenzhen BGI Gene Technology Co., Ltd. and other related parties[15]. - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[40]. - The company received a net compensation of $325 million from Illumina, significantly impacting net profit and cash flow[9][10]. - The company received a net compensation of USD 325 million from Illumina as part of a settlement agreement[16]. - The company has canceled the qualifications of 16 incentive objects due to personal reasons, resulting in the cancellation of 228,100 stock options[16].